Drugs / SEPANTRONIUM
SEPANTRONIUM
also known as
YM155 · Bromure de sepantronium · Bromuro de sepantronio · Sepantronium Bromide · Sepantronium cation · Sepantronium ion
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01023386 | Nov 2009 → Mar 2010 | cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01100931 | Feb 2010 → Dec 2012 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00514267 | May 2007 → Mar 2010 | prostate cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT05263583 | Dec 2022 → Mar 2025 overdue | Burkitt lymphoma, high grade B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, high-grade B-cell lymphoma double-hit/triple-hit +1 | Cothera Bioscience, Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01038804 | Dec 2009 → Jun 2012 | breast cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT01007292 | Nov 2009 → Mar 2013 | non-Hodgkin lymphoma | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT01009775 | Nov 2009 → Mar 2011 | melanoma | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00498914 | Jun 2007 → Apr 2009 | diffuse large B-cell lymphoma | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00328588 | Dec 2006 → Mar 2007 | non-small cell lung carcinoma | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00818480 | Feb 2006 → Mar 2011 | melanoma, non-Hodgkin lymphoma, prostate cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00281541 | Nov 2005 → Jun 2007 | melanoma | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00257478 | ? → Mar 2007 | prostate cancer | Astellas Pharma Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-29 | Cothera Bioscience, Inc | Regulatory Cothera Bioscience Announces Orphan Drug Designation for PC-002 for the Treatment of Burkitt Lymphoma cotherabio.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-29 | Cothera Bioscience, Inc | Cothera Bioscience Announces Orphan Drug Designation for PC-002 for the Treatment of Burkitt Lymphoma cotherabio.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEPANTRONIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110734 ↗ |
| Known as | Bromure de sepantronium | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110734 ↗ |
| Known as | Bromuro de sepantronio | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110734 ↗ |
| Known as | Sepantronium Bromide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05263583 ↗ |
| Known as | Sepantronium cation | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110734 ↗ |
| Known as | Sepantronium ion | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110734 ↗ |
| Known as | YM155 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00257478 ↗ |
| Action | Inhibit | “YM155 is a transcriptional inhibitor of survivin, an inhibitor of apoptosis protein.” NCT01100931 ↗ |
| Modality | Small molecule | — CHEMBL2110734 ↗ |
| Route | Intravenous | “Continuous IV infusion” NCT00498914 ↗ |